Abstract
Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.
Original language | English (US) |
---|---|
Pages (from-to) | 1267-1269 |
Number of pages | 3 |
Journal | Neurology |
Volume | 64 |
Issue number | 7 |
DOIs | |
State | Published - Apr 12 2005 |
ASJC Scopus subject areas
- Clinical Neurology